These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 16987867)

  • 1. In vitro activity and synergism of amphotericin B, azoles and cationic antimicrobials against the emerging pathogen Trichoderma spp.
    Kratzer C; Tobudic S; Schmoll M; Graninger W; Georgopoulos A
    J Antimicrob Chemother; 2006 Nov; 58(5):1058-61. PubMed ID: 16987867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Short communication: In vitro activity of amphotericin B with fluconazole or voriconazole combinations against Candida albicans isolates].
    Oz Y; Akşit F; Kiraz N; Kiremitçi A
    Mikrobiyol Bul; 2008 Jan; 42(1):149-55. PubMed ID: 18444574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of miltefosine as a single agent and in combination with voriconazole or posaconazole against uncommon filamentous fungal pathogens.
    Biswas C; Sorrell TC; Djordjevic JT; Zuo X; Jolliffe KA; Chen SC
    J Antimicrob Chemother; 2013 Dec; 68(12):2842-6. PubMed ID: 23861311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.
    Espinel-Ingroff A
    J Clin Microbiol; 2001 Mar; 39(3):954-8. PubMed ID: 11230410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro synergisms obtained by amphotericin B and voriconazole associated with non-antifungal agents against Fusarium spp.
    Venturini TP; Rossato L; Spader TB; Tronco-Alves GR; Azevedo MI; Weiler CB; Santurio JM; Alves SH
    Diagn Microbiol Infect Dis; 2011 Oct; 71(2):126-30. PubMed ID: 21840673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs.
    Drogari-Apiranthitou M; Mantopoulou FD; Skiada A; Kanioura L; Grammatikou M; Vrioni G; Mitroussia-Ziouva A; Tsakris A; Petrikkos G
    J Antimicrob Chemother; 2012 Aug; 67(8):1937-40. PubMed ID: 22535624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
    Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
    Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan.
    Yamazaki T; Inagaki Y; Fujii T; Ohwada J; Tsukazaki M; Umeda I; Kobayashi K; Shimma N; Page MG; Arisawa M
    Int J Antimicrob Agents; 2010 Oct; 36(4):324-31. PubMed ID: 20674282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro evaluation of combination antifungal activity against Fusarium species isolated from ocular tissues of keratomycosis patients.
    Li L; Wang Z; Li R; Luo S; Sun X
    Am J Ophthalmol; 2008 Nov; 146(5):724-8. PubMed ID: 18707669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the E-test with the NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi.
    Espinel-Ingroff A
    J Clin Microbiol; 2001 Apr; 39(4):1360-7. PubMed ID: 11283057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro antifungal activity of Indian liposomal amphotericin B against clinical isolates of emerging species of yeast and moulds, and its comparison with amphotericin B deoxycholate, voriconazole, itraconazole and fluconazole.
    Rudramurthy SM; Jatana M; Singh R; Chakrabarti A
    Mycoses; 2013 Jan; 56(1):39-46. PubMed ID: 22519679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of Combined Antifungal Agents Against Multidrug-Resistant Candida glabrata Strains.
    Denardi LB; Keller JT; Oliveira V; Mario DAN; Santurio JM; Alves SH
    Mycopathologia; 2017 Oct; 182(9-10):819-828. PubMed ID: 28493006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of voriconazole against yeasts, moulds and dermatophytes in comparison with fluconazole, amphotericin B and griseofulvin.
    Wildfeuer A; Seidl HP; Paule I; Haberreiter A
    Arzneimittelforschung; 1997 Nov; 47(11):1257-63. PubMed ID: 9428984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of antifungal combinations against Candida albicans biofilms.
    Tobudic S; Kratzer C; Lassnigg A; Graninger W; Presterl E
    J Antimicrob Chemother; 2010 Feb; 65(2):271-4. PubMed ID: 19996142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study).
    Swinne D; Watelle M; Van der Flaes M; Nolard N
    Mycoses; 2004 Jun; 47(5-6):177-83. PubMed ID: 15189180
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Gao L; Xia X; Gong X; Zhang H; Sun Y
    Front Cell Infect Microbiol; 2024; 14():1296151. PubMed ID: 38304196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species.
    O'Shaughnessy EM; Meletiadis J; Stergiopoulou T; Demchok JP; Walsh TJ
    J Antimicrob Chemother; 2006 Dec; 58(6):1168-76. PubMed ID: 17071635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Identification and antifungal susceptibility of Candida spp isolated from invasive mycoses. Influence of growth inhibition percentage to determine minimal inhibitory concentration].
    Alvarado D; Díaz MC; Silva V
    Rev Med Chil; 2002 Apr; 130(4):416-23. PubMed ID: 12090107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens.
    Pfaller MA; Messer SA; Georgopapadakou N; Martell LA; Besterman JM; Diekema DJ
    J Clin Microbiol; 2009 Dec; 47(12):3797-804. PubMed ID: 19794038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.